<DOC>
	<DOCNO>NCT02171429</DOCNO>
	<brief_summary>This phase III , double blind , placebo active comparator control , multicenter study investigate efficacy safety etrolizumab induction remission participant moderately severely active UC na√Øve TNF inhibitor refractory intolerant prior immunosuppressant and/or corticosteroid treatment .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Etrolizumab With Adalimumab Placebo Participants With Moderate Severe Ulcerative Colitis ( UC ) Participants Naive Tumor Necrosis Factor ( TNF ) Inhibitors ( Study # 2 )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis UC establish least 6 month prior randomization Moderately severely active UC determine MCS Naive treatment antiTNF therapy An inadequate response , loss response , intolerance prior corticosteroid and/or immunosuppressant treatment Background UC therapy may include oral 5aminosalisylate ( ASA ) , oral corticosteroid , budesonide multimatrix system ( MMX ) , probiotic , azathioprine ( AZA ) , 6mercaptopurine ( MP ) , methotrexate ( MTX ) dose stable 8 week immediately prior randomization Use highly effective contraception method define protocol Have receive colonoscopy within past year willing undergo colonoscopy lieu flexible sigmoidoscopy screen A history current condition disease affect digestive tract , indeterminate colitis , suspicion ischemic , radiation microscopic colitis , Crohn 's disease , fistulas abdominal abscess , colonic mucosal dysplasia , stricture ( stenosis ) colon , toxic megacolon , unremoved adenomatous colonic polyp Prior plan surgery UC Past present ileostomy colostomy Have receive nonpermitted inflammatory bowel disease ( IBD ) antiintegrin therapy ( include natalizumab , vedolizumab , efalizumab ) state protocol Congenital acquire immune deficiency , chronic hepatitis B C infection , HIV positive Evidence treatment Clostridium difficile within 60 day prior randomization intestinal pathogen within 30 day prior randomization History active latent tuberculosis ( TB ) , recurrent opportunistic infection , severe disseminate viral infection organ transplant Any major episode infection require hospitalization treatment intravenous ( IV ) antibiotic within 8 week prior screen oral antibiotic within 4 week prior screen Received live attenuate vaccine within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>